October 16th, 2014

HEALTH, CLIMATE AND INNOVATION

Óscar David SánchezCentro de Investigación Príncipe Felipe

1. Introduction to Health Research1. Health and Biomedical research at a

glance2. The CIPF

2. Health and Climate Research3. Innovation strategy at the CIPF

1. The CIPF science park2. Spin-off creation model

1. Introduction to Health Research

HEALTH RESEARCH

Improve our understanding of the causes and mechanisms underlying health, healthy ageing and disease

Enhance our ability to monitor health and to prevent, detect, treat and manage disease

Support (older) persons to remain active and healthy

Test and demonstrate new models and tools for health and care delivery

BIOMEDICAL RESEARCH

Basic• Understanding of the cellular, molecular and physiological mechanisms underpinning human health and disease

Preclinical• Preparing the ground for clinical research with patients

• Pharmaceutical testing

Clinical• Carried out with patients

• Supervised by doctors in a medical setting

• Clinical testing

Translational Research

THE CIPF

• Private not-for-profit research foundation

• Attached to the Regional Ministry of Health

• Focused on Basic and Translational Biomedical Research

OUR RESEARCH

• Genes, targets, molecular and cellular processes

• Drug and diagnostics development, nanomedicine, regenerative medicine and computational medicine

• Cancer, rare diseases, metabolic diseases, aging and cognitive and functional declining

• Scientific and technological expertise applied to agrofood, environment, cosmetics…

SCIENTIFIC PROGRAMMES

•Developing new diagnostic and therapeutio aproach for high prevalence/impact diseases

Advanced Therapies

•Using genomic data to gain insight in the processes by which the genotype shapes the phenotype, with particular interests in the study of disease mechanisms

Computational Genomics

•Investigating at the molecular and cellular levels the mechanisms underlying the essential cellular processes and their changes in human pathologies

Molecular Mechanisms

•Advancing in the biological and clinical knowledge of the RD, promoting research on diagnostic tests, biomarkers and therapies in the context of genomics and personalized medicine

Rare and Genetic Diseases

•Basic and translational research on cognitive, motor, sleep and circadian rhythms alterations in different pathological situations

NeurologicalImpairment

BIOMEDICAL RESEARCH

Basic Preclinical Clinical

Advanced Therapies

Computational Genomics

Molecular Mechanisms

Rare and Genetic Diseases

NeurologicalImpairment

FIGURES

• 21 research labs and 9 technological

services

• ≈ 200 staff (85% devoted to

research)

• 10M€ budget (≈ 55% from external

funding)

RESULTS

• ≈ 100 research projects/year

• ≈ 100 international publications/year

• Growing patent portfolio

• 4 spin-off companies

2. Health and Climate Research

THE CHALLENGE

• Environmental factors (pollution, climate-related factors, noise, chemicals, radiation and exposure to green spaces) can have an adverse (or a positive) impact on human health– One-quarter of the global non-communicable

disease burden, and more than one-third of the burden among children, is due to modifiable environmental and life-style factors.

• Huge potential for prevention to improve lifelong health, wellbeing, and life expectancy… And to tackle raising healthcare costs.

EU RESEARCH AGENDA (I)

• EU has been funding multidisciplinary research on climate, environment and health since early FP5

• A cross-cutting issue that has emerged especially in FP7 is the impact of global change (especially climate change) on health.

EU RESEARCH AGENDA (II)

• Three priorities in FP7– Health impacts of climate change– Health effects of environmental

stressors other than climate change (e.g., chemicals, air pollution, electromagnetic fields)

–Methods and decision-support tools for environmental health risk analysis and policy development

FP7 PROJECTS (I)

• ARCRISK and CLEAR– Potential health effects related to changing chemical

exposures of Arctic populations due to climate change

• ICEPURE– Changing UV radiation patterns with consequent risk of

developing skin malignancies

• URGENCHE– Developing and applying a methodological framework

for the assessment of the overall risks and benefits of alternative greenhouse gas emission reduction policies for health and well-being.

• PURGE– Examining the health impacts of GHG reduction policies

in urban settings in Europe, China and India, using case studies of 3-4 large and three smaller urban centres.

• ATOPICA:– Exploring the combined pan-European impact of

changes in climate, land use and air pollution on allergen pollen-induced diseases through a chain of quantitative physical and statistical models.

FP7 PROJECTS (II)

• EDENEXT – Focused on the emergence and risk of spread of vector-

borne diseases in Europe

• QWECI– Aims to understand at a more fundamental level the

climate drivers of the vector-borne diseases malaria, Rift Valley Fever and certain tick-borne diseases in Africa, which all have major human and livestock health and economic implications.

• HEALTHY FUTURES– Construct a disease risk mapping system for three water-

related high-impact vector borne diseases (malaria, Rift valley fever and schistosomiasis), accounting for environmental/climatic trends and changes in socio-economic conditions to predict future risk.

• VIROCLIME– Investigated the impact of climate change on viral fluxes in

water.

• EO2HEAVEN – Case study focusing on links between certain

environmental, including climatic, variables and the outbreak of cholera in Africa.

EU EXPOSOME INITIATIVE

• Large-scale initiative, budget of €38 million until 2018, is the largest ever initiative in the environment and health research area in the EU. – EXPOSOMICS: Enhanced exposure

assessment and omic profiling for high priority environmental exposures in Europe

– HELIX: The human early-life exposome – novel tools for integrating early-life environmental exposures and child health across Europe

– HEALS: Health and environment-wide associations based on large population surveys

HORIZON 2020

• Environment and health research activities will be addressed mainly under the Societal Challenge 1 (Health, Demographic Change and Wellbeing).

• Relevant call topics also be published under other challenges and actions – Climate action, environment, resource efficiency

and raw materials– Leadership in enabling and industrial technologies

(ICT and nanotechnologies)– Food security, sustainable agriculture, marine and

maritime research and the bioeconomy.

WORKPROGRAMME 2014-2015 CLIMATE IN HEALTH

• PHC 31 – 2014: Foresight for health policy development and regulation– Goal: The complex interactions between

multiple determinants of health and wellbeing are not well understood. These include but are not limited to air quality, climate change, traffic and congestion, ambient noise, built environment…

– Outcome: Key driving forces- (external and internal to the health systems) likely to influence health and wellbeing in Europe and beyond in the future.

WORKPROGRAMME 2014-2015 CLIMATE IN HEALTH

• PHC 4 – 2015: Health promotion and disease prevention: improved inter-sector co-operation for environment and health based interventions– Outcome: On the basis of quantitative and

qualitative indicators, evidence on effective interventions taking a ‘health in all’ approach, linking environment, climate and health, allowing informed decisions on multi-sector interventions and related policies.

– Scope: integration of environment, climate and health sectors (including but not limited to air quality, water and sanitation, chemicals, occupational factors, etc.)

3. Innovation strategy at the CIPF

TECH TRANSFER IN BIOMEDICINE

Basic Preclinical Clinical

TECH TRANSFER IN BIOMEDICINE

Basic Preclinical

Clinical Ph. 1

Clinical Ph. 2

Clinical Ph. 3-4 Market

“Academic” patents

Big pharma companiesBig pharma companies

Early-stage development companies

TECH TRANSFER IN BIOMEDICINE

Company creation is one of the best tech transfer mechanisms in

Health/Biotech

SPIN-OFF CREATION MODEL

• Technology/Licensing agreement

– Otherwise it’s a start-up

• Collaboration agrement– Company-CIPF collaborations,

confidentiality, conflicts of interests…

• Shareholder agreement– The CIPF holds equity

THE CIPF SCIENCE PARK

A business-oriented environment for the growth of start-ups and

established companies in the fields of Healthcare and Biotechnology

You’re a research center…

Why are you housing companies?

THE QUESTION

What does a (new) (biotech) company need?

1. Money2. A good team

3. Sound science4. Technology

OUR APPROACH

• We offer to companies what we offer to (our) research labs

– Lab and office space– Scientific equipment– Access to technological services (animal

facilities, cytomics, screening, genomics and genetics, confocal and electron microscopy, proteomics, NMR, GMP facilities…)

– Coffee sharing! A collaborative environment with researchers

THE MODEL

• No renting, but a collaboration agreement

– Monthly fee depending on what the company is using

– Technological and scientific infrastructure as a service

– If a company needs something, they ask for it and they get it

OUR GOALS

• Put together early stage spin-off/start-up with big/leading companies

• Aligned with the CIPF research mission

• Make innovation and technology transfer happen:– CIPF Company – Company + CIPF Market

1. Introduction to Health Research1. Health and Biomedical research at a

glance2. The CIPF

2. Health and Climate Research3. Innovation strategy at the CIPF

1. The CIPF science park2. Spin-off creation model

THANKS!

Óscar David Sánchezosanchez@cipf.es